Review Article
Mycobacterium bovis Bacille Calmette-Guérin as a Vaccine Vector for Global Infectious Disease Control
Table 1
Summary of candidate TB vaccines in clinical trials 2009. Nine candidate preventive TB vaccines are currently in clinical phases.
| Status | Products | Product description | Sponsor |
| Phase IIb | MVA85A/AERAS-485 | Vaccinia virus MVA | OETC/AERAS | Phase IIb | AERAS-402/Crucell Ad35 | rBCG/adenovirus 35 | Crucell/AERAS |
| Phase II | Hybrid-I + IC31 | Ag85B/ESAT6 + adjuvant | SSI/TBVI | Phase II | M72 | Fusion protein + adjuvant | GSK/AERAS |
| Phase I | AdAg85A | adenovirus 5/Ag85A | McMaster Univ. | Phase I | VPM 1002 | rBCG/listeriolysin::ΔureC | Max Planck/TBVI | Phase I | Hyvac 4/AERAS-404 | Fusion protein + adjuvant | SSI/Sanofi/AERAS | Phase I | RUTI | Fragmented Mtb cell | Archivel Farma | Phase I | Hybrid-I + CAF01 | Ag85B/ESAT6 + adjuvant | SSI |
|
|
Abbreviations in the sponsors: AERAS, AERAS Global TB Vaccine Foundation; GSK, GlaxoSmithKline; OETC, The Oxford-Emergent Tuberculosis Consortium Ltd.; SSI, Staten Serum Institute; TBVI, Tuberculosis Vaccine Initiative.
|